ximos 250 mg 5 ml granulado para suspensão oral - rezultati pretrage

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

optimon plus 10 mg + 12,5 mg tablete

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb - lisinoprilum, hydrochlorothiazidum - tableta - 10 mg + 12,5 mg - urbroj: jedna tableta sadrži 10 mg lizinoprila u obliku lizinopril dihidrata i 12,5 mg hidroklorotiazida

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

timadren 5 mg/1 ml kapi za oči , rastvor

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - timolol - kapi za oči , rastvor - 5 mg/1 ml - 1 ml kapi za oči, rastvora sadrži: 5 mg timolola (u obliku timololmaleata)

panadol 500 mg/1 tableta filmom obložena tableta

clinres farmacija d.o.o. - paracetamol - filmom obložena tableta - 500 mg/1 tableta - 1 filmom obložena tableta sadrži: 500 mg paracetamola

Europska Unija - hrvatski - EMA (European Medicines Agency)

hyrimoz

sandoz gmbh - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; arthritis, juvenile rheumatoid; crohn disease; skin diseases, papulosquamous - imunosupresivi - rheumatoid arthritishyrimoz in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hyrimoz može biti dano kao monoterapija u slučaju netolerancije метотрексата ili pri stalnom liječenju s metotreksat je nepraktično. Адалимумаб, kao što je prikazano, kako bi se smanjila brzina progresije oštećenja zglobova kao što se mjeri x-ray i poboljšati fizičku funkciju, prilikom raspoređivanja u kombinaciji s metotreksatom. juvenile idiopathic arthritis- polyarticular juvenile idiopathic arthritishyrimoz in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). hyrimoz može biti dano kao monoterapija u slučaju netolerancije метотрексата ili pri stalnom liječenju s metotreksat je nepraktično. Адалимумаб ne ima dugu povijest u bolesnika u dobi od manje od 2 godine. - enthesitis-related arthritishyrimoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritis- ankylosing spondylitis (as)hyrimoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. - axial spondyloarthritis without radiographic evidence of ashyrimoz is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs. psoriatic arthritishyrimoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Адалимумаб, kao što je prikazano, kako bi se smanjila brzina progresije periferne lezije zgloba, mjereno pomoću x-zraka u bolesnika s полиартикулярным mogućnost simetrične podtipovi bolesti i poboljšati tjelesne funkcije. psoriasishyrimoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasishyrimoz is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)hyrimoz is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy. crohn’s diseasehyrimoz is indicated for treatment of moderately to severely active crohn’s disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseasehyrimoz is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies. paediatric ulcerative colitishyrimoz is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. ulcerative colitishyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitishyrimoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitishyrimoz is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

vfend 40 mg/1 ml prašak za oralnu suspenziju

pfizer bh d.o.o. sarajevo - vorikonazol - prašak za oralnu suspenziju - 40 mg/1 ml - 1 ml oralne suspenzije sadrži: 40 mg vorikonazola

dorzovis combo 20 mg/1 ml+ 5 mg/1 ml kapi za oči, rastvor

pharmavision bh d.o.o. - dorzolamid, timolol - kapi za oči, rastvor - 20 mg/1 ml+ 5 mg/1 ml - 1 ml kapi za oči, rastvora sadrži: 20 mg dorzolamida (u obliku dorzolamid hidrohlorida) 5 mg timolola (u obliku timolol maleata)

dorzovis combo 20 mg/1 ml+ 5 mg/1 ml kapi za oči, rastvor

rissar 1 mg/1 ml oralni rastvor

alkaloid d.o.o. sarajevo, isevića sokak 6, sarajevo - risperidonskoj - oralni rastvor - 1 mg/1 ml - 1 ml oralnog rastvora sadrži: 1 mg risperidon

vitamin ad 22522 i.j./1 ml+ 5000 i.j./1 ml oralne kapi, rastvor

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - ergokalciferol, vitamin a - oralne kapi, rastvor - 22522 i.j./1 ml+ 5000 i.j./1 ml - 1 ml oralnih kapi, rastvora sadrži: 22 522 i.j. vitamin a (u obliku retinolacetata) 5 000 i.j. ergokalciferol

tylol hot d 500 mg/1 kesa+ 60 mg/1 kesa+ 4 mg/1 kesa šumeće granule

nobel lijek d.o.o. sarajevo - hlorfenamin, paracetamol, pseudoefedrin - šumeće granule - 500 mg/1 kesa+ 60 mg/1 kesa+ 4 mg/1 kesa - 1 kesica sa 6 g šumećih granula sadrži: 500 mg paracetamola 60 mg pseudoefedrina (u obliku pseudoefedrin hidrohlorida) 4 mg hlorfenamina (u obliku hlorfenamin maleata)